BioAtla shares surge 11.70% premarket after positive Type B FDA meeting for Ozuriftamab Vedotin in OPSCC.

BioAtla (NASDAQ:BCAB) surged 11.7% in premarket trading following a regulatory update on its clinical development plan for ozuriftamab vedotin in oropharyngeal squamous cell carcinoma (OPSCC), announced one hour prior. The update came after a productive Type B (End of Phase 2) meeting with the FDA, signaling regulatory alignment and progress toward advancing the drug candidate. This development, coupled with recent positive preliminary data from Phase 1 trials of BA3182 and ongoing Phase 2 trial results for ozuriftamab vedotin in HPV-associated OPSCC, reinforced investor confidence in the company’s pipeline. While earlier news, such as a shareholder-approved share issuance and delayed reverse split, had limited immediate impact, the FDA meeting outcome directly addressed near-term clinical and regulatory milestones, aligning with the stock’s sharp premarket rise.